General Toxicity Notes
Blood pressure is the best guide to dose and interval. Hypotensive effects magnified by natriuretic agents or sodium depletion. Can cause hyperkalemia, metabolic acidosis. Acute renal dysfunction with bilateral or transplant renal artery stenosis, low renal perfusion pressure.
Half-Life (Normalesrd) Hours
5-9/No data
Plasma Protein Binding %
98
Volume Of Distribution L/Kg
4.4
Dose For Normal Renal Function
600 mg q24h
Second Dose
Second Dose: 400-800 mg q24h
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [A]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50,titrate, [D]
References
Kovacs SJ, Tenero DM, Martin DE, Ilson BE, Jorkasky DK. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease. Pharmacotherapy. 1999; 19: 612-9. [PMID: 10331824] / Martin DE, Chapelsky MC, Ilson B, Tenero D, Boike SC, Zariffa N, et al. Phar-macokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment. J Clin Pharmacol. 1998; 38: 129-37. [PMID: 9549643] / Tenero D, Martin D, Ilson B, Jushchyshyn J, Boike S, Lundberg D, et al. Phar-macokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm Drug Dispos. 1998; 19: 351-6. [PMID: 9737815]
Toxicity Notes
Eprosartan pharmacokinetics more variable in ESRD. Decreased protein binding in uremia.